Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sonesitatug Vedotin - Lepu Biopharma

Next Previous
Drug Profile

Sonesitatug Vedotin - Lepu Biopharma

Alternative Names: AZD-0901; CMG 901; Sone-ve

Latest Information Update: 09 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KeyMed Biosciences; Miracogen
  • Developer AstraZeneca; KeyMed Biosciences
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotherapies; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Adenocarcinoma
  • Phase II Solid tumours

Most Recent Events

  • 09 Mar 2026 AstraZeneca initiates phase-III CLARITY-Gastric 02 clinical trials in Adenocarcinoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, First-line therapy, Combination therapy) in Taiwan (IV) (NCT07431281)
  • 03 Feb 2026 Phase-III clinical trials in Adenocarcinoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, First-line therapy, Combination therapy) in Canada (IV) (NCT07431281)
  • 29 Aug 2025 Phase-II clinical trials in Adenocarcinoma (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Russia (IV) (NCT07143604)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top